Systemic cancer treatment linked to 5% skeletal muscle loss over 90 daysCancer treatment linked to muscle loss in large analysis

This systematic review and meta-analysis examined the association between systemic cancer treatment and changes in skeletal muscle mass (SMM) in patients with cancer. The analysis included 78 studies with a total of 10,502 patients receiving chemotherapy and/or immunotherapy, with or without targeted therapy. The median interval between assessments was 90 days (IQR: 71-129). No comparator group was included; the analysis focused on longitudinal change within patients.

The primary outcome was change in SMM during systemic cancer treatment. The pooled standardized mean change (SMC) was -0.24 (95% CI: -0.29 to -0.20), indicating a small decline in muscle mass. This corresponds to an absolute loss of approximately 5% over the median 90-day interval. The effect size is considered small according to Cohen's thresholds.

No secondary outcomes were reported in the meta-analysis. Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. The review did not assess clinical outcomes such as survival, quality of life, or treatment toxicity.

Compared to prior literature, this finding aligns with known catabolic effects of cancer and its treatments, but the high heterogeneity (I²=92%) suggests that the true effect varies considerably across studies. This limits the interpretability of a single pooled estimate. The authors note that prospective studies with standardized methods are needed to better characterize muscle loss.

Key methodological limitations include substantial heterogeneity, lack of a comparator group, and reliance on observational data. The pooled estimate represents an association, not causation. Effect sizes were generally small, and the clinical significance of a 5% loss over 90 days may vary by patient population.

For clinical practice, these results suggest that muscle loss is a measurable consequence of systemic cancer treatment, though the magnitude is modest on average. Clinicians should consider monitoring SMM in patients undergoing treatment, especially those at risk for sarcopenia. However, the high heterogeneity means individual patient trajectories may differ substantially.

Unanswered questions include the impact of specific treatment regimens, the role of targeted therapies, the relationship between muscle loss and clinical outcomes, and whether interventions such as exercise or nutrition can mitigate this decline. Future research should focus on standardized assessment methods and prospective designs.